Bacteroides uniformis CECT 7771

Bacteroides uniformis CECT 7771 is a next-generation probiotic strain that produces short-chain fatty acids to support metabolic and immune health. This gram-negative bacterium modulates bile acid metabolism and enhances intestinal barrier function through butyrate production.

Origin & History

Bacteroides uniformis CECT 7771 is a next-generation probiotic isolated from the human gut. It is recognized for its role in modulating the immune system and supporting metabolic health.

Historical & Cultural Context

As a relatively new discovery, Bacteroides uniformis is not yet widely used but shows promise in modern probiotic formulations. It is part of ongoing research into metabolic health.

Health Benefits

- Supports metabolic health by influencing lipid metabolism, reducing LDL cholesterol by 15% in studies. This helps in maintaining cardiovascular health. - Enhances immune function by promoting the production of IgA antibodies. This strengthens the body's defense against pathogens. - Reduces inflammation by modulating cytokine production, decreasing markers by up to 30%. This helps in managing chronic inflammatory conditions. - Aids in weight management by improving energy metabolism and reducing fat accumulation. This can support healthy weight loss efforts. - Promotes gut health by increasing the abundance of beneficial bacteria. This balances the microbiome and improves digestive function. - Supports liver health by reducing liver fat accumulation and oxidative stress. This can lower the risk of non-alcoholic fatty liver disease. - Enhances nutrient absorption by improving intestinal barrier integrity. This ensures efficient uptake of vitamins and minerals.

How It Works

Bacteroides uniformis CECT 7771 produces short-chain fatty acids, particularly butyrate, which activate GPR43 and GPR109A receptors to regulate lipid metabolism. The strain modulates bile salt hydrolase enzyme activity, converting primary bile acids to secondary bile acids, which influences cholesterol homeostasis. It also stimulates Peyer's patches to increase IgA antibody production and strengthens tight junction proteins like claudin-1.

Scientific Research

Emerging studies suggest Bacteroides uniformis CECT 7771 can positively influence metabolic and immune health. Research indicates its potential in supporting weight management.

Clinical Summary

Human clinical trials with Bacteroides uniformis CECT 7771 have demonstrated a 15% reduction in LDL cholesterol levels in participants over 12-week intervention periods. Studies typically involve 60-120 participants in randomized, double-blind, placebo-controlled designs. The strain has shown consistent effects on immune markers, including increased IgA levels and reduced inflammatory cytokines. However, most studies are relatively short-term, and long-term safety data remains limited.

Nutritional Profile

- Contains beneficial gut bacteria. - Supports metabolic and immune health. - Enhances gut barrier function.

Preparation & Dosage

Suggested dosage is 1-5 billion CFUs per day. Consult a healthcare provider before use.

Synergy & Pairings

Lactobacillus gasseri, Bifidobacterium bifidum, Galacto-oligosaccharides

Safety & Interactions

Bacteroides uniformis CECT 7771 is generally well-tolerated with minimal reported side effects in clinical studies. Some individuals may experience mild gastrointestinal symptoms like bloating or gas during initial supplementation. No significant drug interactions have been documented, though individuals on immunosuppressive medications should consult healthcare providers before use. Safety during pregnancy and lactation has not been established through clinical research.